Doribax news from FiercePharma
News
FDA won't expand Doribax use now
The FDA hasn't exactly said "no" to Johnson & Johnson's Doribax, but it has definitely said "not yet." J&J had asked the agency to expand the use of the IV antibiotic to hospital-acquired... Read more...
Panel gives mixed blessing to J&J's Doribax
Johnson & Johnson's Doribax squeaked through an FDA advisory panel yesterday, winning its blessing as an effective treatment for hospital-acquired pneumonia on a 7-6 vote. And at least one... Read more...
J&J's consumer sales drive earnings growth
Mixed news on Johnson & Johnson today, too: Reporting its second-quarter results this morning, J&J announced a healthy 8 percent hike in net income on strong sales of its consumer products.... Read more...
Get more Doribax coverage at:
Paid Research Reports
- Leading Drug Delivery Companies and Technologies: Competitive landscape, company profiles and technological developments
- Drug Repositioning Strategies - Serendipity by design
- eHealthInsight Series: Online Patient Recruitment Strategies - Optimizing the clinical trial process
- Pricing & Reimbursement - Seven Major Markets Update
- Innovative Clinical Trial Design and Management: Trends, success stories and impact upon R&D budgets
